These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 18314612)

  • 1. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
    Sotlar K
    Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis, clinical features, and treatment advances in mastocytosis.
    Pardanani A; Akin C; Valent P
    Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mastocytosis.
    Metcalfe DD
    Novartis Found Symp; 2005; 271():232-42; discussion 242-9. PubMed ID: 16605139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel approaches in the treatment of systemic mastocytosis.
    Quintas-Cardama A; Aribi A; Cortes J; Giles FJ; Kantarjian H; Verstovsek S
    Cancer; 2006 Oct; 107(7):1429-39. PubMed ID: 16948123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
    Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
    Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIT mutations in mastocytosis and their potential as therapeutic targets.
    Gotlib J
    Immunol Allergy Clin North Am; 2006 Aug; 26(3):575-92. PubMed ID: 16931294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
    Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
    Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mastocytosis - an update.
    Amon U; Hartmann K; Horny HP; Nowak A
    J Dtsch Dermatol Ges; 2010 Sep; 8(9):695-711; quiz 712. PubMed ID: 20678151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.
    Arock M; Valent P
    Expert Rev Hematol; 2010 Aug; 3(4):497-516. PubMed ID: 21083038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
    Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P
    Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
    Zermati Y; De Sepulveda P; Féger F; Létard S; Kersual J; Castéran N; Gorochov G; Dy M; Ribadeau Dumas A; Dorgham K; Parizot C; Bieche Y; Vidaud M; Lortholary O; Arock M; Hermine O; Dubreuil P
    Oncogene; 2003 Feb; 22(5):660-4. PubMed ID: 12569358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIT and mastocytosis.
    Lim KH; Pardanani A; Tefferi A
    Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
    Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.
    Corless CL; Harrell P; Lacouture M; Bainbridge T; Le C; Gatter K; White C; Granter S; Heinrich MC
    J Mol Diagn; 2006 Nov; 8(5):604-12. PubMed ID: 17065430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic mastocytosis: current classification and novel therapeutic options.
    Barbie DA; Deangelo DJ
    Clin Adv Hematol Oncol; 2006 Oct; 4(10):768-75. PubMed ID: 17099633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
    Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
    Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mastocytosis: pathology, genetics, and current options for therapy.
    Valent P; Akin C; Sperr WR; Mayerhofer M; Födinger M; Fritsche-Polanz R; Sotlar K; Escribano L; Arock M; Horny HP; Metcalfe DD
    Leuk Lymphoma; 2005 Jan; 46(1):35-48. PubMed ID: 15621779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.
    Valent P; Sperr WR; Schwartz LB; Horny HP
    J Allergy Clin Immunol; 2004 Jul; 114(1):3-11; quiz 12. PubMed ID: 15241337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
    Pedersen M; Rönnstrand L; Sun J
    Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.